QIAstat-Dx Respiratory SARS-CoV-2 Panel

Be the first to know about QIAstat-Dx updates

Co-infections and COVID-19

Clinicians want accurate and timely answers.
Patients want the right treatment.

Powered by proven QIAGEN sample and assay technologies, you can now confidently provide clinical insights to patients with the highest level of versatility and harness the full potential of multiplex syndromic testing.

Learn more about QIAstat-Dx

Confronting emerging COVID-19 variants

During this unprecedented COVID-19 pandemic, data on novel SARS-CoV-2 variants with potentially increased transmissibility is rapidly developing. Confronting these new variants demands constant surveillance on diagnostic impact. Learn how our medical teams are working around the clock to empower your diagnostic labs.

Stay up to date on our continuous surveillance assessing the impact of mutations on assay sensitivity. (Updated January 2021)

Read the report

 

QIAstat-Dx Respiratory SARS-CoV-2 Panel
(Emergency Use Authorization)

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 21 respiratory targets, including SARS-CoV-2.

Learn more

*Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Meet the challenges that this unusual flu season will bring

The overlap of COVID-19 and influenza season is especially concerning as we may soon face two epidemics, or what some are calling a “twindemic”. Read about recent studies and what to expect this flu season in our resource hub.

Learn more

Customer story: Avoiding repeat hospital visits with syndromic testing

How can labs get the results that doctors and patients need for effective treatment? Hear how Mako Medical, a full-service reference lab in North Carolina, delivers fast respiratory results for senior care populations.

Read the story

QIAGEN is committed to supporting healthcare workers fight COVID-19

Visit www.qiagen.com/coronavirus to learn more about how QIAGEN solutions can be used in the fight against COVID-19, or get in touch to let us know how we can support your lab.

QIAstat-Dx – changing the landscape of multiplex respiratory testing

Multiplex syndromic testing rapidly and simultaneously surveys a large number of pathogens, giving you the answers you need when you need them. Check out our infographic and learn more about syndromic testing for respiratory disease on the QIAstat-Dx!

Download Infographic

See QIAstat-Dx in action

Be the first to know about QIAstat-Dx news and webinars

Send me updates
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
  • This test has not been FDA cleared or approved;
  • This test has been authorized by FDA under an EUA for use by authorized laboratories;
  • This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
  • Social Sharing